产品描述说明： CD20 is a 33-37 kD, four transmembrane spanning protein, also known as B1 and Bp35. CD20 is expressed on pre-B-cells, resting and activated B cells (not plasma cells), some follicular dendritic cells, and at low levels on a T cell subset. CD20 is heavily phosphorylated on activated B cells and malignant B cells. Homo-oligomeric complexes of CD20 are thought to form Ca2+ conductive ion channels in the plasma membrane of B cells. The CD20 molecule is involved in B-cell activation and is associated with various Src family kinases (Lyn, Lck, Fyn). It exists in a complex with MHC class I and II, CD53, CD81, and CD82. Anti-CD20 antibody, Rituximab, sold under the brand name Rituxan, is a medication used to treat certain autoimmune diseases and types of cancer. It is used for non-Hodgkin lymphoma, chronic lymphocytic leukemia (in non-geriatric patients), rheumatoid arthritis, granulomatosis with polyangiitis, idiopathic thrombocytopenic purpura, pemphigus vulgaris, myasthenia gravis and Epstein–Barr virus-positive mucocutaneous ulcers. Biosimilars of Rituxan include Blitzima, Riabni, Ritemvia, Rituenza (F.K.A. Tuxella), Rixathon, Ruxience, and Truxima. This antibody is made from a Rituximab Fab fragment making it specific, efficient, and effective. Recombinant Anti-CD20 Fab fragment Antibody is useful for researchers interested in autoimmune disease and cancer research. 品牌简介： 一家老牌抗体原产企业，专注于研发多种指标单克隆抗体和多克隆抗体，产品涉及细胞通路、细胞生物学、神经生物学、表观遗传学、癌症等多个领域；标签抗体和GFP抗体种类丰富；同时专注各类荧光二抗和Trueblot特色产品的开发。